New drug rozanolixizumab tested for rare Muscle-Weakening disease in china

NCT ID NCT07246564

Recruiting now Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug rozanolixizumab in 40 Chinese adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive the drug as a shot under the skin. The main goal is to see if it improves their ability to do daily activities after about 6 weeks. This is an early, small study without a comparison group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rozanolixizumab
What this could lead to: If successful, this could provide a new treatment option for Chinese patients with generalized myasthenia gravis, improving daily function.
What could go wrong: This is a small, single-arm, open-label study with no placebo group, so results may be less reliable. It only covers one treatment cycle, and long-term safety and efficacy are not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS

Contacts and locations

Locations

Mg0033 20040
RECRUITING

Beijing, China
Mg0033 20172
RECRUITING

Shanghai, China
Mg0033 20180
RECRUITING

Wuhan, China
Mg0033 20184
RECRUITING

Shenzhen, China
Mg0033 20185
RECRUITING

Jinan, China
Mg0033 20204
RECRUITING

Suzhou, China
Mg0033 20261
RECRUITING

Changchun, China
Mg0033 20269
RECRUITING

Guangzhou, China
Mg0033 20295
RECRUITING

Changsha, China
Mg0033 20347
RECRUITING

Jinan, China
Mg0033 20348
RECRUITING

Fuzhou, China
Mg0033 20349
RECRUITING

Xuzhou SHI, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.